<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR9">
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Chen</surname>
    <given-names>CN</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>CPC</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>KK</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>WC</given-names>
   </name>
   <name>
    <surname>Hsieh</surname>
    <given-names>HP</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>PH</given-names>
   </name>
   <name>
    <surname>Hsu</surname>
    <given-names>JTA</given-names>
   </name>
  </person-group>
  <article-title>Inhibition of SARS-CoV 3C-like protease activity by theaflavin-3,3â€²-digallate (TF3)</article-title>
  <source>Evid Based Complement Alternat Med</source>
  <year>2005</year>
  <volume>2</volume>
  <fpage>209</fpage>
  <lpage>215</lpage>
  <pub-id pub-id-type="doi">10.1093/ecam/neh081</pub-id>
  <?supplied-pmid 1142193?>
  <pub-id pub-id-type="pmid">15937562</pub-id>
 </element-citation>
</ref>
